Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany. Issue 11 (6th September 2021)

• Record Type: Journal Article
• Authors: Singh, Prianka; McDonald, Laura; Waldenberger, Daniela; Welslau, Manfred; von der Heyde, Eyck; Gauler, Thomas; Dietz, Andreas
• Is Part Of: Head & neck. Volume 43:Issue 11(2021)
• Page Start: 3540
• Page End: 3551
• Publication Date: 2021-09-06
• Subjects: nivolumab -- overall survival -- PD‐1 targeting agent -- progression‐free survival -- SCCHN; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26853
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: In the Phase‐III clinical trial, CheckMate 141, nivolumab significantly improved survival versus standard of care in patients with platinum‐refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods: This pooled analysis investigated the real‐world effectiveness of nivolumab, following prior platinum‐based therapy, in patients with R/M SCCHN from the United States (US) Flatiron Health database and German HANNA prospective observational study. Results: Overall, 782 patients (56% US; 44% Germany) were included. Median overall survival (OS) was 8.71 months, and progression‐free survival was 4.11 months. Eastern Cooperative Oncology Group Performance Status 0 or 1, platinum sensitivity, and older age were associated with longer OS, in which number of prior lines of therapy had no significant effect. Conclusion: These findings demonstrate survival benefits of nivolumab in patients with R/M SCCHN in the real‐world setting. The observed real‐world effectiveness of nivolumab aligns with the efficacy of nivolumab in CheckMate 141.